Chong Kun Dang announced on the 23rd that the results of phase 3 clinical trials of the macular degeneration treatment Lucentis biosimilar CKD-701 were published in the SCI-level international academic journal PLoS One. Chong Kun Dang conducted phase 3 clinical trials of CKD-701 in 312 patients with neovascular age-related macular degeneration at 25 hospitals, including Seoul National University Hospital, from September 2018 to March 2021. In phase 3 clinical trials, the percentage of patients with vision loss of fewer than 15 characters in the primary efficacy evaluation index comparing the maximum calibration vision (BCVA) at 3 months after drug administration was 97.95% (143/146) in the CKD-701 administration group